Bioray Biotech CoROCO:7561 83 ROA % is 4.91% as of Dec. 2025, which is 2628% above its 10-year median of 0.18. GuruFocus rates ROCO:7561 with a GF Score™ of 83/100 and a GF Value™ of NT$29.48 (Significantly Undervalued). Among 1,005 Drug Manufacturers companies, Bioray Biotech Co ranks better than 67.46% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bioray Biotech Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$26.0 Mil.
Bioray Biotech Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$530.3 Mil. Therefore, Bioray Biotech Co's annualized ROA % for the quarter that ended in Dec. 2025 was 4.91%.
The historical rank and industry rank for Bioray Biotech Co's ROA % or its related term are showing as below:
ROCO:7561'
s ROA % Range Over the Past 10 Years
Min: -2.03 Med: 0.18 Max: 6.03
Current: 6.03
During the past 9 years, Bioray Biotech Co's highest ROA % was 6.03%. The lowest was -2.03%. And the median was 0.18%.
ROCO:7561's ROA % is ranked better than 67.46% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs ROCO:7561: 6.03
Bioray Biotech Co (ROCO:7561) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Bioray Biotech Co ROA % Related Terms
Bioray Biotech Co ROA % Historical Data
* Premium members only.
The historical data trend for Bioray Biotech Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's ROA % distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Bioray Biotech Co (ROCO:7561) has a ROA % of 4.91% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bioray Biotech Co and its competitors. This is 2628% above median its historical median of 0.18. According to the industry distribution chart, Bioray Biotech Co ranks #327 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Bioray Biotech Co's ROA % too high?
Bioray Biotech Co's current ROA % of 4.91% is 2628% above median its 10-year median of 0.18. The Drug Manufacturers industry median ROA % is 2.72. Bioray Biotech Co's value of 4.91% is 80.5% above this industry median. Based on the distribution chart, Bioray Biotech Co ranks #327 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bioray Biotech Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #327 out of 1005 companies for ROA %. This puts Bioray Biotech Co in the upper half of its industry. The industry median ROA % is 2.72. Bioray Biotech Co's value of 4.91% is 80.5% above this benchmark. While the company's 10-year median is 0.18 vs. the industry median of 2.72, Bioray Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current ROA % of 4.91% is 80.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bioray Biotech Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current ROA % is 4.91%, which is 2628% above median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.48, compared to a current price of NT$18.05 — trading 38.8% below its estimated fair value. The current ROA % is 4.91%, which is 2628% above median its 10-year median of 0.18 and 80.5% above the Drug Manufacturers industry median of 2.72. Bioray Biotech Co's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current ROA % is 4.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$18.05 is trading 38.8% below its estimated GF Value™ of NT$29.48.
GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:7561:
ROA %: 4.91% (2628% above median its 10-year median of 0.18)
GF Value™: NT$29.48 vs. price of NT$18.05 (38.8% below fair value)
Industry Position: 80.5% above the Drug Manufacturers median (#327 of 1005)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
83GF Score
Get the complete analysis for ROCO:7561
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
